Seaside Therapeutics was founded to translate promising research discoveries into effective treatments for patients with autism, fragile X syndrome, and other disorders of brain development.

We are initially focused on recent breakthrough discoveries of our Scientific Founder, Mark Bear, Picower Professor of Neuroscience at the Massachusetts Institute of Technology and Investigator, Howard Hughes Medical Institute. Dr. Bear discovered a link between genetic mutations found in individuals with fragile X syndrome, a specific disorder of brain development, and dysfunction in the metabotropic glutamate (mGluR) neurotransmitter system. Independent international researchers have confirmed that pharmacologic intervention with compounds targeting specific mGluR receptors normalizes behavior and brain development in animal models, thus validating the "mGluR theory of fragile X". Our selective mGluR antagonist STX107, licensed from Merck & Co., Inc. is in advanced stages of preclinical development and has demonstrated profound efficacy in animal models of fragile X, thus providing compelling justification for advancing our drug into human trials.

Seaside intends to leverage our scientific expertise to identify additional novel therapies and rapidly advance pharmacologically relevant medications into clinical trials. To assure that we assemble the assets and resources necessary for success, we have developed a unique business model emphasizing strategic collaborations with pharmaceutical and biotechnology companies, research institutions, government agencies, foundations and advocacy groups.

With our in depth expertise in the neurobiology of cognitive development and our extensive experience in all aspects of pharmaceutical product development we are ideally suited to deliver on our vision to successfully develop breakthrough medications that will meaningfully improve the lives of individuals with disorders of brain development. »